Search

Your search keyword '"Antiresorptive drugs"' showing total 296 results

Search Constraints

Start Over You searched for: Descriptor "Antiresorptive drugs" Remove constraint Descriptor: "Antiresorptive drugs"
296 results on '"Antiresorptive drugs"'

Search Results

2. Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System.

3. The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence.

5. The effect of antiresorptive therapy on the prevalence and severity of oral lichen planus: a retrospective study

6. Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw

7. Sclerotic bone: a sign of bone reaction in patients with medication related osteonecrosis of the jaw.

11. Medication‐related osteonecrosis of the jaw triggered by endodontic failure in oncologic patients.

12. Untreated osteoporosis and higher FRAX as risk factors for tooth loss: a 5-year prospective study.

13. Location and Gender Differences in Osteonecrosis of the Jaws in Patients Treated with Antiresorptive and Antineoplastic Drugs Undergoing Dentoalveolar Surgical, Systematic Review with Meta-Analysis and Trial Sequential Analysis.

14. The Use of Human Amniotic Membrane (hAM) as a Treatment Strategy of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis of the Literature.

16. Prevention of aromatase inhibitor–induced bone loss with anti-resorptive therapy in post-menopausal women with early-stage breast cancer.

17. Osteoporose: Diagnostik und Behandlung.

18. Clinical and Radiographic Outcomes of Dental Implants in Patients Treated With Antiresorptive Drugs: A Consecutive Case Series.

19. Osteonecrosis of the jaws in patients under osteoporosis treatment: a nine-year experience report

20. Anti-osteoporotic treatment and COVID-19 risk: is there an association?

21. Treatment Consideration in Postmenopausal Osteoporosis Patients at Imminent Fracture Risk

22. Osteoporose: Diagnostik und Behandlung.

23. Medication-Related Osteonecrosis of the Jaw in Patients Treated Concurrently with Antiresorptive and Antiangiogenic Agents: Systematic Review and Meta-Analysis

24. Real-world study of antiresorptive-related osteonecrosis of jaw based on the US food and drug administration adverse event reporting system database.

25. Novosti u farmakološkom liječenju osteoporoze.

26. Peri‐implantitis‐like medication‐related osteonecrosis of the jaw: Clinical considerations and histological evaluation with confocal laser scanning microscope.

27. The Effect of Patient-associated Factors on Long-term Survival of Dental Implants.

28. Epidemiology, etiopathogenesis, and management of MRONJ: A European multicenter study.

29. Bisphosphonate- and disumab-related gingival disorders: case analysis from the U.S. Food and Drug Administration Adverse Event Reporting System.

30. The emerging role of osteoclasts in the treatment of bone metastases: rationale and recent clinical evidence.

32. The Use of Human Amniotic Membrane (hAM) as a Treatment Strategy of Medication-Related Osteonecrosis of the Jaw (MRONJ): A Systematic Review and Meta-Analysis of the Literature

33. Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs.

34. Anti-osteoporotic treatment and COVID-19 risk: is there an association?

35. Executive summary clinical practice guideline of postmenopausal, glucocorticoid-induced, and male osteoporosis (2022 update): Spanish Society for Bone and Mineral Metabolism Investigation (SEIOMM).

36. Influence of symptomatic periodontal disease on changes in skeletal bone density during medication therapy for osteoporosis in postmenopausal women: the Japanese Osteoporosis Intervention Trial (JOINT)-04 and JOINT-05.

37. Pharmacological Therapy of Osteoporosis: What’s New?

38. Surgical therapy for medication-related osteonecrosis of the jaw in osteoporotic patients treated with antiresorptive agents

39. Medication-related osteonecrosis of the jaw: A review about etiology, risk factors, pathophysiology, and treatment

40. Medication-Related Osteonecrosis of the Jaw: Bibliometric Analysis from 2003 to 2023.

41. Recent Progresses in the Treatment of Osteoporosis

42. Therapeutic Approach in the Treatment of Medication-Related Osteonecrosis of the Jaw: Case Series of 3 Patients and State of the Art on Surgical Strategies

43. Recent Progresses in the Treatment of Osteoporosis.

44. Evaluation of segmental mandibular resection without microvascular reconstruction in patients affected by medication-related osteonecrosis of the jaw: a systematic review.

45. Dental Implant Placement in Patients With a History of Medications Related to Osteonecrosis of the Jaws: A Systematic Review.

46. Therapeutic Approach in the Treatment of Medication-Related Osteonecrosis of the Jaw: Case Series of 3 Patients and State of the Art on Surgical Strategies.

47. The role of antiresorptive drugs and medication-related osteonecrosis of the jaw in nononcologic immunosuppressed patients: A systematic review.

48. The risk of osteonecrosis of the jaw and adverse outcomes in patients using antiresorptive drugs undergoing orthodontic treatment: A systematic review

49. Analysis of Serum Proteome after Treatment of Osteoporosis with Anabolic or Antiresorptive Drugs

50. Awareness of Medication Related Osteonecrosıs of the Jaw among Dentist Working at Public Oral and Dental Health Care Centers in Ankara, Turkey.

Catalog

Books, media, physical & digital resources